Public Policy and Big Pharma M&A: Prices, Patents and Taxes
This article was originally published in RPM Report
Executive Summary
Big Pharma M&A is back in the headlines, though so far the biggest deals have been talked about but not completed. While the business elements of each of the deals are different, there are some common public policy themes.